VISEN Pharmaceuticals Closes $150 Million Series B Financing to Accelerate the Development and Commercialization of its Innovative Endocrinology Therapies in Greater China

PR Newswire
January 9, 2021 — 11:06 CST

UNLOCK DATA
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech

Want to read this important story?

Access thousands of news articles and data posts over the past 9 years!

Already have an account or paid subscription? Log in

Related Topics: biotech California Casino China chinese Denmark finance Germany healthcare Hong Kong investment IPO Macau manufacturing medicine OrbiMed pharmaceutical Private Equity Sequoia Sequoia Capital China Shanghai stock market taiwan technology venture capital

Related News:

AVAPOW’s Black Friday Event: Essential Automotive Tools At Exclusive Prices

November 22, 2024 — 04:00

Harbour BioMed Announces Submission of IND Application for HBM9378/SKB378 in the Treatment of Chronic Obstructive Pulmonary Disease

November 8, 2024 — 17:45

New features revealed for PaperCut Hive cloud print management solution

November 8, 2024 — 06:32

LPS Launches NeuroNode: Empowering Advanced AI for Enterprises with On-Premises LLM

November 7, 2024 — 17:39

Cybellum Receives Frost & Sullivan’s Competitive Strategy Award for its Innovative Product Security Solutions

September 27, 2024 — 01:00

Live from ESMO 2024 | Ascentage Pharma Releases Latest Data Showing Sustained Clinical Efficacy of Olverembatinib in SDH-Deficient GIST during a Mini Oral Presentation

September 14, 2024 — 08:18

Desay Battery Highlights Advanced Energy Solutions at RE+ 2024

September 11, 2024 — 03:00

Announcement of ICAIRE’s Classification as a UNESCO Category 2 Center at the Global AI Summit

September 11, 2024 — 02:34

Transcenta Holding Limited (Stock Code: 6628.HK) Announce 2024 Interim Results

August 29, 2024 — 14:31

Franchising and Licensing Asia (FLAsia) 2024